

Supplementary Table 12. Comparison of predictive performance between new eGFR equations for KFRT

KFRT	eGFR	Unadjusted				Adjusted ^a			
		IDI (95% CI)	p-value	Continuous NRI (95% CI)	p-value	IDI (95% CI)	p-value	Continuous NRI (95% CI)	p-value
2 yr	eGFR _{cr} (NEW) vs. eGFR _{cr-cys} (NEW)	-0.010 (-0.022 to 0.000)	0.06	-0.030 (-0.163 to 0.084)	0.57	-0.015 (-0.025 to -0.003)	0.01	-0.121 (-0.228 to 0.034)	0.10
5 yr	eGFR _{cr} (NEW) vs. eGFR _{cr-cys} (NEW)	0.004 (-0.007 to 0.015)	0.61	0.091 (0.001-0.195)	0.04	-0.001 (-0.009 to 0.007)	0.87	0.028 (-0.082 to 0.121)	0.69
8 yr	eGFR _{cr} (NEW) vs. eGFR _{cr-cys} (NEW)	0.012 (0.001-0.023)	0.03	0.14 (0.039-0.238)	<0.001	0.003 (-0.006 to 0.012)	0.52	0.087 (-0.016 to 0.193)	0.08

CI, confidence interval; eGFR, estimated glomerular filtration rate; eGFR_{cr}, eGFR based on creatinine with current equation; eGFR_{cr} (NEW), eGFR based on creatinine with new equation; eGFR_{cr-cys}, eGFR based on creatinine and cystatin C with current equation; eGFR_{cr-cys} (NEW), eGFR based on creatinine and cystatin C with new equation; IDI, integrated discrimination improvement; KFRT, kidney failure with replacement therapy; NRI, net reclassification index.

^aAdjusted for age, sex, history of cardiovascular disease, diabetes mellitus, body mass index, systolic blood pressure, serum total cholesterol, calcium-phosphate product, urine protein-to-creatinine ratio, use of renin-angiotensin system blockade or statin.